Taken together, our results clearly suggested that NC promoted erythroid differentiation and apoptosis through c-Myc-miRNAs regulatory axis, providing potential benefits in both imatinib-sensitive and -resistant CML patients. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.